GlassScriptPhysician profile
Jamie Brockman
NPI 1053075820
$3,859.10
in general payments reported to CMS, 2019-2025
25 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $477 · 2023: $374 · 2024: $1,302 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,382.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $963.44 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $502.34 | 2022-2025 | |
| Amgen INC. | $381.24 | 2023-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $368.60 | 2022-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $320.12 | 2022-2025 | Watchman Access System |
| Lilly USA, LLC | $221.37 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.79 | 2025 | Caplyta |
| Abbott Laboratories | $136.69 | 2024-2025 | Freestyle Libre 3, Assurity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.66 | 2022-2025 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $111.32 | 2024-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Sumitomo Pharma America, INC. | $100.74 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $94.41 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.69 | 2022-2024 | Trulance, Xifaxan |
| Exact Sciences Corporation | $60.71 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $51.28 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $30.55 | 2025 | Rexulti |
| Nevro Corp. | $26.35 | 2022 | |
| Inspire Medical Systems, INC. | $25.38 | 2025 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.48 | 2025 | Lifevest |
| Dexcom, INC. | $17.41 | 2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $14.71 | 2022 | |
| Insulet Corporation | $14.66 | 2024 | Omnipod |
| Amneal Pharmaceuticals LLC | $14.24 | 2024 | Unithroid |
| Edwards Lifesciences Corporation | $14.04 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Seqirus USA INC | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Brockman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.